The long-acting antiretroviral cabotegravir and rilpivirine combination has just received FDA,
EMA and Health Canada approval. This novel drug delivery approach is about to …

Introduction Poor or inconsistent adherence to daily oral pre-exposure prophylaxis (PrEP)
has emerged as a key barrier to effective HIV prevention. The advent of potent long-acting …

Self‐assembled prodrug nanoparticles with tumor‐responsive capacity have great potential
in tumor visualization and treatment. However, the nanoparticle formulas usually contain …

Ultra-long-acting integrase strand transfer inhibitors were created by screening a library of
monomeric and dimeric dolutegravir (DTG) prodrug nanoformulations. This led to an 18 …

Vaccines and antivirals are the classical weapons deployed to contain, prevent, and treat life-
threatening viral illnesses. Specifically, for SARS-CoV-2 infection, vaccines protect against …

The research and development of non-viral gene therapy has been extensive over the past
decade and has received a big push thanks to the recent successful approval of non-viral …

Introduction We see a development in the field of long-acting products to serve patients with
chronic diseases by providing benefits in adherence, efficacy, and safety of the treatment …

Peptides and peptide-based materials have an increasing role in the treatment of viral
infections through their use as active pharmaceutical ingredients, targeting moieties …

Viral hepatitis is among the top four causes of mortality globally, causing 1.4 million deaths
each year, exceeding tuberculosis, malaria and human immunodeficiency virus. Hepatitis B …

Formulating aqueous suspensions is an attractive strategy to incorporate poorly water-
soluble drugs, where the drug release can be tailored to maintain desired release profiles of …